AI Article Synopsis
- The review talks about how liver problems (like cirrhosis) can lead to a type of diabetes called hepatogenous diabetes (HD).
- It shows how the body’s use of insulin and sugar is messed up in both cirrhosis and type II diabetes, hinting that they may have similar causes.
- Finally, it stresses the importance of figuring out and treating these issues in patients with liver cirrhosis to help them stay healthy.
Article Abstract
The review focused mainly on the pathogenesis of hepatogenous diabetes (HD) in liver cirrhosis (LC). This review reveals parallels between the mechanisms of metabolic dysfunction observed in LC and type II diabetes (T2DM), suggesting a shared pathway leading to HD. It underscores the role of insulin in HD pathogenesis, highlighting key factors such as insulin signaling, glucose metabolism, insulin resistance (IR), and the influence of adipocytes. Furthermore, the impact of adipose tissue accumulation, fatty acid metabolism, and pro-inflammatory cytokines like Tumor necrosis factor-α (TNF-α) on IR are discussed in the context of HD. Altered signaling pathways, disruptions in the endocrine system, liver inflammation, changes in muscle mass and composition, and modifications to the gut microbiota collectively contribute to the complex interplay linking cirrhosis and HD. This study highlights how important it is to identify and treat this complex condition in cirrhotic patients by thoroughly analyzing the link between cirrhosis, IR, and HD. It also emphasizes the vitality of targeted interventions. Cellular and molecular investigations into IR have revealed potential therapeutic targets for managing and preventing HD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.lfs.2024.122934 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unraveling the mechanisms of hepatogenous diabetes and its therapeutic perspectives.
Life Sci
September 2024
Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India. Electronic address:
Article Synopsis
- The review talks about how liver problems (like cirrhosis) can lead to a type of diabetes called hepatogenous diabetes (HD).
- It shows how the body’s use of insulin and sugar is messed up in both cirrhosis and type II diabetes, hinting that they may have similar causes.
- Finally, it stresses the importance of figuring out and treating these issues in patients with liver cirrhosis to help them stay healthy.
Hepatogenous Diabetes as Compared to Type-2 Diabetes Mellitus and Non-diabetes in Patients With Liver Cirrhosis: Magnitude, Characteristics, and Implications.
J Clin Exp Hepatol
April 2024
Department of Gastroenterology, All India Institute of Medical Sciences, Patna, India.
Aim: Hepatogenous diabetes (HD) is frequently underestimated among cirrhosis patients. The current study assessed the magnitude, clinical characteristics, and implications of HD in cirrhosis patients as compared to the patients with type-2 diabetes mellitus (T2DM) and non-diabetes (ND) cirrhosis.
Methods: In a prospective observational study, 338 consecutive eligible cirrhosis patients were screened for diabetes mellitus.
Advances in the treatment of hepatogenous diabetes: A review.
Medicine (Baltimore)
November 2023
Department of Clinical Nutrition, West China Hospital; Sichuan University, Chengdu, Sichuan Province, China.
Article Synopsis
- Hepatogenous diabetes (HD) is a disorder related to glycogen metabolism, commonly seen in patients with cirrhosis due to chronic liver disease.* -
- Patients with HD face a poor prognosis and are at increased risk for serious complications like gastrointestinal bleeding and hepatic encephalopathy, as their condition often worsens along with cirrhosis.* -
- Despite the severity of HD, there is currently no established treatment strategy, prompting this paper to review recent advancements in treatment options to enhance patient outcomes.*
Subclinical diabetes confirmed by 75-g OGTT influence on the prognosis of decompensated cirrhosis.
J Gastroenterol Hepatol
January 2024
Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea.
Background And Aim: Disorders of glucose metabolism, such as impaired glucose tolerance (IGT) and diabetes mellitus (DM), frequently occur in cirrhosis. We aimed to evaluate who needs to be undertaken a 75-g oral glucose tolerance test (OGTT) to find underlying subclinical diabetes.
Methods: This prospective study included 713 patients with either compensated (Child-Turcotte-Pugh [CTP] class A) or decompensated cirrhosis (CTP class B/C) without previous DM history.
[Expert consensus on the management of diabetes mellitus in patients with liver cirrhosis].
Zhonghua Gan Zang Bing Za Zhi
August 2022
In view of the high prevalence of diabetes mellitus in patients with liver cirrhosis and the increasing trend of non-alcoholic fatty liver disease-associated cirrhosis, the diagnosis and treatment of diabetes mellitus in patients with liver cirrhosis are becoming widespread concerns. Therefore, the Chronic Disease Management Branch, China Pharmaceutical Biotechnology Association, organized multidisciplinary experts from gastroenterology, infective disease, endocrinology, etc, to draw up expert consensus on the management of diabetes mellitus in patients with liver cirrhosis, with focusing on the classification and management of hyperglycemia in cirrhotic patients. The consensus summarizes the prevalence, pathogenesis, clinical setting and prognosis of the concomitant diabetes mellitus in patients with liver cirrhosis, and definitely puts forward a proposal regarding "hepatogenous diabetes" as one of the four subtypes of diabetes mellitus in cirrhotic patients, and further recommends the basic principles for diagnosing and monitoring diabetes mellitus and the selection of antidiabetic drugs based on liver functions in patients with liver cirrhosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!